A new study from Brazil is reporting significant positive effects of hydroxychloroquine (HCQ) + azithromycin (AZM) on early-stage suspected COVID19 cases. The study was posted as a preliminary manuscript draft on Dropbox a couple of days ago. I just tweeted my thoughts in a long thread, but here is a bit more polished version.
Update 20 April: It was announced today that the study described below has been suspended because of ethical violations. As pointed out by Natalia Pasternak and Carlos Orsi and Ricardo Parolin Schnekenberg (see Additional Reading links below), the study had already started before the ethical approval had been obtained. This could be figured out by looking at the disclosed study days in the preprint and the trial registration at the Clinical Trials website.
Continue reading “Thoughts on the Prevent Senior study”
The IHU Mediterranee Infection, the Marseille hospital that claims that hydroxychloroquine + azithromycin treatment will cure almost everyone infected with COVID-19 has been reporting very low death rates for COVID-19 patients. As of today, their website reports that the IHU has a much lower death – 1.7% – than the worldwide COVID-19 mortality rate of 6.2%.
While that might look amazing at first glance, these numbers are not surprising, given the high numbers of virus tests that the institute has been performing. Let’s take a closer look at their testing to better understand how the Marseille hospital can get such low mortality rate numbers.
Continue reading “Amazing rates”
In a new segment on this site, I will start handing out “This Image Is Fine” awards for papers containing images of concern, but where the Editors do not think there is a problem. This first installment of the “This Image Is Fine” award will go to the Journal of the American College of Cardiology (JACC) for deciding that images containing large amounts of duplicated elements are not worth investigating.
Continue reading “JACC wins the first “This Image Is Fine” Award”
The International Society of Antimicrobial Chemotherapy (ISAC) has shared concerns about the Gautret et al. paper published in its own journal. This paper, published under senior authorship of Didier Raoult from the IHU-Méditerranée Infection in Marseille, describes a small study that showed remarkable effects of Hydroxychloroquine and Azithromycin treatment in COVID-19 patients.
After world leaders and politicians started to tweet and endorse this study, many people pressured health officials to start treating COVID-19 patients with this regime, although the study was small and not yet confirmed by independent, larger, and better randomized other studies.
Several scientists and medical professionals, including myself, had concerns about how patients were assigned to each treatment group, how PCR results were reported, why patients with a poor outcome had been left out of the final results, and how this treatment could potentially result in serious side effects. I wrote about my concerns in this blogpost and on PubPeer.
Now, ISAC, who is overseeing the International Journal of Antimicrobial Agents, the journal that published this study, has joined in those concerns.
Continue reading “ISAC shares concerns about the Hydroxychloroquine and Azithromycin paper”
This blog post is based on a Twitter thread I did on March 27, 2020, after seeing Mathieu Rebeaud’s Tweet about a new white paper from the institute of Didier Raoult. That not-yet peer reviewed paper describes a group of 80 COVID-19 patients, all treated with a combination of hydroxychloroquine and azithromycin. This treatment had shown some promising results in a very small, not well-executed study by the same group. Unfortunately, this second study does not have a control group and the patients did not appear to be very sick. So here is my critical review.
Continue reading “An observational study without a control group”
We are in the midst of a viral pandemic with huge effects on human health, social interactions, and the economy. Suddenly, lots of people have opinions or claim to have solutions to solve the COVID-19 situation. Not surprisingly, the Coronavirus epidemic has led to an enormous input of scientific papers, editorials, letters, reviews, trials, and what have you not. Most of these have been written hastily, without the rigor and thoughtfulness and editing that are normally essential to scientific publishing. Some of these papers are great, many of them not so much. Social media is exploding with all kinds of post-publication reviews of heavily discussed scientific papers. This post is an attempt to collect critical reviews of some of these COVID-19 related scientific papers.
Continue reading “Post-publication reviews on COVID-19 papers”
There has been a lot of excitement – and even a presidential tweet about a recent paper from the lab of Didier Raoult, an infectious disease specialist in Marseille, France. But although this study might offer a glimmer of hope, there are some serious problems with the paper too.
Continue reading “Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections”
Dr. 艾芬 (Ai Fen) has played a key role in ringing the alarm in the 2020 COVID-19 outbreak. But blog posts about Dr. Ai Fen ‘s role in the COVID-19 outbreak have been mysteriously disappearing. This post is my contribution to make sure that the Internet Never Forgets.
Continue reading “Dr. Ai Fen, 艾芬, the Wuhan Whistle”
Some new developments on the COVID-19 TCM paper that I wrote about yesterday. The patient case and their CT scan image appear to have been copied from another paper by another group.
Continue reading “Update on the COVID-19 TCM paper”
The recent COVID-19 outbreak has led to an enormous amount of preprints and rapidly-approved papers of variable quality. A recently published paper in Pharmacological Research called “Traditional Chinese Medicine for COVID-19 Treatment” caught my eye. The title suggested that Traditional Chinese Medicine (TCM) could be used to treat patients that had fallen ill with the viral disease, but a quick read showed that the paper promised much more than it delivered. Here is a critical review.
Continue reading “Some critical notes on a COVID-19 TCM paper”